Alcidol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alcidol

Property Description
Active Ingredient Alfacalcidol (1alpha-hydroxycholecalciferol)
Form Capsules, Oral Drops, Solution for Injection
Pharmacological Class Vitamin D Analogue, Calcemic Agent
Origin Synthetic Analogue (Prodrug)
Route Oral, Parenteral (Injection)

What Type of Medicine is Alcidol and What is its Composition?

Alcidol is a pharmaceutical preparation classified as a Vitamin D analogue and a calcemic agent, designed to help the body manage its essential mineral supplies. The active ingredient in this medicine is Alfacalcidol, which is a synthetic analogue also known chemically as 1alpha-hydroxycholecalciferol. This class of drug is used specifically to regulate the body's use of calcium. Alcidol is typically a single-ingredient product, available in several high-level forms for administration, including soft capsules and oral drops for oral use, and a solution for injection.

Alfacalcidol's Unique Nature: Analogue vs. Natural Vitamin D

Alfacalcidol is defined as a prodrug that offers a key advantage over the natural Vitamin D compound (Cholecalciferol or D3) due to its metabolic efficiency. Unlike natural Vitamin D, which requires an activation step in the kidneys, Alfacalcidol is pre-activated and requires only the first metabolic step in the liver to yield the fully active form, calcitriol. This unique chemical trait ensures the medicine remains effective even when a patient has compromised renal function, a common scenario in which standard Vitamin D supplementation may fail.

General Purpose: Supporting the Body’s Mineral Balance

The general purpose of Alcidol is to ensure the body can effectively achieve and maintain a healthy balance of calcium and phosphate minerals. By providing a readily convertible, active form of the Vitamin D hormone, the medicine significantly enhances the body's intestinal absorption of these key minerals. The resulting benefit is direct support for bone health, helping to prevent mineral deficiencies that can lead to the softening or weakening of the skeletal structure.

Regulatory References

  1. NIH MedlinePlus Drug Information: Calcitriol

What side effects are possible with Alcidol?

Possible Side Effects and Safety Information

The safety profile of Alcidol (Alfacalcidol) is predominantly defined by its action as a calcemic agent, meaning its adverse effects are similar to those associated with excessive intake of Vitamin D. The primary safety focus centers on the regulation of mineral balance.

Frequency-Classified Adverse Reactions

The following effects are officially documented and classified according to regulatory frequency standards:

  • Common (may affect up to 1 in 10 people): Hypercalcaemia (elevated blood calcium), Hyperphosphataemia, Hypercalciuria, rash, pruritus (itching), and abdominal pain or discomfort.
  • Uncommon (may affect up to 1 in 100 people): Nausea, vomiting, diarrhoea, constipation, headache, and a confusional state.

Serious Adverse Reactions and Safety Constraints

The most significant safety concern is the consequence of prolonged hypercalcaemia. This condition is documented to potentially aggravate existing conditions such as arteriosclerosis and cardiac valve sclerosis, and increases the risk of metastatic calcification (calcium deposits in soft tissues) and kidney stone formation. Renal impairment, including acute renal failure, has been reported as a post-marketing event of not known frequency.

Alcidol is formally contraindicated in individuals with pre-existing high blood calcium levels (hypercalcaemia) and in those with documented metastatic calcification. Regular monitoring of serum calcium, phosphate, and creatinine levels is required throughout treatment to manage these risks.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Alcidol (Alfacalcidol) is typically associated with the development of hypercalcemia, a potentially serious condition resulting from elevated calcium levels in the blood. Because symptoms can vary significantly or be delayed, any suspected overdose is a medical emergency.

Documented Overdose Signs

Signs of hypercalcemia can include non-specific symptoms such as headache, weakness, excessive thirst (polydipsia), and frequent urination (polyuria). Gastrointestinal signs commonly include loss of appetite, nausea, vomiting, constipation, and occasionally diarrhea. In more severe or prolonged cases, overdose can lead to critical effects on the kidneys, potentially causing nephrocalcinosis or nephrolithiasis (kidney stones), and may affect heart function and blood pressure.

Required Emergency Action

Immediate medical attention is required if an overdose is suspected or confirmed. If too much medication has been taken, a healthcare professional may recommend immediate measures to reduce drug absorption, such as gastric lavage (stomach pumping) or administration of mineral oil, depending on the time elapsed since ingestion. The main treatment involves stopping the medication and managing the resulting hypercalcemia through diet, increased fluid intake, and close monitoring of renal function, electrolytes, and cardiac rhythm. Prolonged hypercalcemia requires sustained supportive care to prevent permanent organ damage.

Therapeutic Uses of Alcidol

The core therapeutic benefit of Alcidol (Alfacalcidol) is to provide supportive relief in conditions where symptoms related to systemic imbalance are noticeable. The medication is considered relevant across therapeutic domains involving symptoms related to systemic imbalance, including conditions such as renal osteodystrophy, hypocalcaemia, hypoparathyroidism, osteomalacia, and certain forms of rickets.

This supportive therapeutic domain is applied in clinical settings marked by increased discomfort, particularly in patients with reduced renal function. It is applied in scenarios where additional management of discomfort is required, which may interfere with daily comfort.

“This approach plays a role in managing conditions that require short-term symptomatic assistance to ease the overall symptom load and support improved day-to-day comfort.”

For instance, Alcidol is commonly used to help manage symptoms of heightened physiological activity, such as muscle spasms or tetany, associated with low blood calcium. This application may assist with maintaining a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases.


QuickFact: Support for Symptoms of Neuromuscular Distress

Quick Fact: Support for Symptoms of Neuromuscular Distress This medicine is relevant for easing challenging symptoms of heightened physiological activity, such as cramping and tetany, relevant in contexts involving heightened systemic burden.

Regulatory References

  1. Irish Medicines Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Alcidol?

This section outlines the officially documented population eligibility rules for Alcidol (Alfacalcidol), based strictly on governmental regulatory labeling.

Absolute Contraindications

Alcidol must not be used by patients with:

  • Hypercalcaemia (abnormally high blood calcium levels).
  • Confirmed Hypervitaminosis D (Vitamin D overdose).
  • Documented metastatic calcification.
  • Known hypersensitivity to Alfacalcidol or any excipients in the specific formulation.

Age and Condition Eligibility

Alcidol is approved for use in adult patients and children (including neonates) for conditions related to disturbed calcium metabolism, such as chronic renal failure. Use in older adults is permitted, though lower starting doses may be appropriate.

Restricted Populations

Use is officially restricted or not recommended in several populations:

  • Pregnancy and Breastfeeding: Use is generally not recommended unless clearly necessary, and breastfeeding should be avoided due to the documented risk of hypercalcaemia in the infant.
  • Comorbidities: Use requires caution in patients with conditions like sarcoidosis (due to increased Vitamin D sensitivity) or pre-existing cardiovascular diseases (such as arteriosclerosis), as high calcium levels may aggravate these conditions. Patients with severe renal impairment must use a phosphate binding agent concurrently.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alcidol’s official interaction profile is structured around avoiding serious calcemic augmentation and managing exposure according to government regulatory documentation.

Contraindicated and Avoided Combinations: Co-administration of Digitalis glycosides is formally contraindicated if hypercalcaemia develops, due to the critical risk of cardiac arrhythmias. Other Vitamin D analogues must not be given concurrently due to the enhanced risk of hypercalcaemia. Magnesium-containing antacids and laxatives should be avoided to prevent hypermagnesaemia.

Pharmacodynamic Augmentation: The concurrent use of Thiazide diuretics and Calcium-containing preparations may enhance the risk of hypercalcaemia due to additive effects on the body’s mineral balance. High intake of Dietary Phosphate is also documented as potentially leading to hyperphosphatemia.

Exposure and Timing Constraints: Interactions categorized as pharmacokinetic involve Anticonvulsants (e.g., Barbiturates), which are officially documented as inducing hepatic detoxification enzymes, altering Alcidol’s metabolism. Alcidol may also increase the serum concentration of Aluminium from other preparations. To prevent interference with intestinal absorption, a mandatory timing rule applies to Bile acid sequestrants such as Cholestyramine: Alcidol must be administered at least 1 hour before or 4 to 6 hours after the sequestrant intake.

Mechanism of Action

How Alcidol Works

Alcidol exerts its pharmacodynamic effects by selectively engaging key molecular targets to modulate specific signaling pathways. Its mechanism of action is focused on two primary domains: receptor-mediated signaling and intrinsic pathway regulation.


Modulation of Receptor-Mediated Signaling

Alcidol functions as a modulator at critical G-protein coupled receptors (GPCRs) localized within targeted cellular systems. This interaction is characterized by a specific binding affinity that does not lead to full agonism or antagonism, but rather an allosteric adjustment of receptor conformation. This precise change in receptor activity initiates or suppresses downstream signaling sequences, resulting in reduced intracellular signaling output and a decrease in the concentration of active mediators within the local signaling environment.


Regulation of Intracellular Pathway Cascades

The drug further influences intrinsic cellular processes by interacting with specific intracellular enzymes crucial for signal amplification. This interaction modifies early molecular steps that define systemic physiological outcomes. By altering the turnover rate of these enzymes, Alcidol establishes a shift in the steady-state kinetics of the targeted pathways, leading to measurable adjustments in downstream physiological parameters and molecular flux.

Dosage and Administration Information

Administration Scope

Alcidol (Alfacalcidol) administration is defined by established protocols, specifying the route, dose, frequency, and required monitoring. The medicine is available as oral soft capsules, oral drops, and a solution for intravenous injection.

Feature Official Guideline
Route of Administration Oral and Parenteral (Intravenous Injection)
Dosing Schedule (Adult Initial) 1.0 mu g/ day (standard) or 0.5 mu g/ day (older adults)
Frequency Pattern Once daily (oral) or Two to three times a week (pulsed intravenous therapy)
Timing in Relation to Meals May be administered with or without food and/or drink

Administration Protocol and Titration

The medicine’s use is a response-guided protocol that mandates regular adjustment based on laboratory markers.

Official Step Sequence:

  • Treatment begins with the specified initial dose, which is defined by age (e.g., 0.05 mu g/ kg/ day for smaller children).
  • The dose is adjusted in increments of 0.25 mu g to 0.5 mu g at intervals of 2 to 4 weeks, guided by monitoring of plasma calcium and Parathyroid Hormone (PTH) levels.
  • Oral soft capsules must be swallowed whole. The injection solution is administered intravenously as a quick bolus.
  • If hypercalcaemia occurs, the drug must be temporarily stopped until calcium levels return to the normal range, and then restarted at half the previous dose.

This protocol establishes a standardized, controlled, and continuously monitored approach to the use of Alcidol, reflecting required standards for dose management and administration across different patient populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Alcidol

Evidence for use in Bone Disorders Related to Kidney Disease

Research has explored how Alcidol was studied in research exploring bone and mineral disorders, such as renal osteodystrophy and secondary hyperparathyroidism, which are common conditions marked by functional limitations in people with advanced kidney disease. These studies typically involved observing outcomes related to systemic or functional imbalance over defined time intervals. The research so far suggests patterns related to outcomes measured in studies of mineral metabolism in patients with kidney disease. Findings describe patterns observed in studies monitoring outcomes related to systemic or functional imbalance, which are linked to parathyroid hormone. These findings describe group patterns, not personal outcomes.

Evidence for use in Low Calcium Conditions (Hypocalcemia)

Alcidol was evaluated in research contexts involving conditions where the blood has low calcium levels, known as hypocalcemia. This includes studies of patients with hypoparathyroidism, a condition associated with acute or disruptive episodes. The findings from these trials often describe patterns related to how calcium levels evolved in the observed populations. Findings describe patterns related to outcomes measured in research exploring short-term symptom changes linked to very low calcium, and outcomes capturing phases of heightened symptom activity. However, data are still emerging, and comparative evidence against other approaches for certain types of hypocalcemia is lacking.

Long-term studies and follow-up

This section summarizes what is known from studies that have followed patients over an extended period. Research has explored long-term outcomes and the durability of the observed responses on bone health and mineral balance. Currently, long-term effects are not fully established, and there is limited information for long-term outcomes that go beyond a few years of observation. While evidence suggests patterns of sustained stability in some mineral levels, the follow-up durations were limited in many key trials.

Frequently Asked Questions (FAQ)

Common questions about Alcidol (FAQ)


Q: How quickly can someone expect Alcidol to start working?

Official regulatory documents indicate that the effects of Alcidol on the body’s ability to absorb calcium and phosphorus may begin within 3 days of starting treatment. In specific cases, like changes in calcium absorption, effects have been noted to appear as quickly as 6 hours after an oral dose, with the effect sometimes peaking around 24 hours.


Q: How long is the typical treatment period with Alcidol?

Alcidol is officially approved for the management of chronic conditions, such as bone disorders related to long-term kidney disease. For this reason, treatment is often long-term in nature. The specific duration of use is guided by the underlying condition being addressed and requires continuous monitoring of your blood mineral levels.


Q: What happens if I miss a scheduled dose of Alcidol?

Patient information generally describes that if a dose is missed, taking it as soon as remembered is the common instruction, unless the next dose is due shortly. If that is the case, instructions suggest skipping the missed dose and continuing with the normal schedule. This is done to prevent taking two doses too close together.


Q: Is Alcidol the type of medication that needs to be tapered off?

The official protocol in regulatory documents specifically addresses stopping the medicine if blood calcium levels become too high (hypercalcaemia). In this scenario, the drug is temporarily stopped and then re-instituted at a lower amount once the calcium levels normalize. There is no standard protocol provided for tapering when discontinuing the medicine for non-adverse reasons.


Q: Does Alcidol cause weight gain or weight loss?

Regulatory safety documents do not list weight gain as a common side effect of the medicine itself. However, weight loss is noted as a potential symptom that can be associated with hypercalcaemia (abnormally high blood calcium), which is the most significant safety concern linked to this class of medication.


Q: Are headaches a common side effect of Alcidol?

According to official regulatory classifications, headache is an uncommon side effect of Alcidol. This means that this effect may affect up to 1 in every 100 people using the medicine.


Q: What kind of monitoring or tests are sometimes needed while taking Alcidol?

Regulatory documents mandate the regular monitoring of certain blood markers throughout the treatment course. The required tests specifically check levels of serum calcium, serum phosphate, and creatinine to ensure mineral balance is maintained.


Q: Can Alcidol be taken with supplements or herbal remedies?

Official warnings focus on specific interactions with other medicines and supplements containing high amounts of calcium, phosphate, and magnesium (like some antacids). Regulatory labeling advises that all concurrent medicines, supplements, or herbals should be known to a healthcare provider.


Q: Can taking Alcidol make someone feel tired or fatigued?

Fatigue and asthenia (general weakness or lack of energy) are noted in regulatory documents as symptoms that may be associated with hypercalcaemia (abnormally high blood calcium). If this occurs, regulatory guidelines mandate that mineral levels must be monitored closely, as dosage adjustment may be part of the response-guided protocol.


Q: Is Alcidol considered a strong medicine?

Alcidol is classified by health authorities as a Vitamin D analogue. Official documents describe it as having a rapid onset of response when compared to other non-activated forms of Vitamin D. This characteristic is what allows for more responsive and accurate dosage adjustments.


Q: How does Alcidol compare to other types of similar treatments?

Regulatory documents highlight a key distinction of Alcidol (Alfacalcidol) from natural Vitamin D. It is designed to require only one activation step in the liver, not the final step in the kidneys. This unique metabolic pathway means that Alcidol can remain effective even for people whose kidney function is compromised.


Q: Is it necessary to take Alcidol every day?

The required frequency depends on the specific formulation being used. The oral capsules or drops are typically administered once daily. However, the solution for intravenous injection is often given two to three times per week as part of a pulsed therapy regimen.


Q: Is Alcidol safe for use by older adults or seniors?

Official documentation describes Alcidol as indicated for use in older adults. The administration guidelines often recommend that this population may be started on a lower initial daily dose compared to the standard adult starting dose, due to potential changes in body function.


Q: Does Alcidol interact with common over-the-counter pain relievers?

Official regulatory documents do not list common over-the-counter pain relievers (like acetaminophen or ibuprofen) as formal contraindications. However, safety summaries sometimes reference studies where Non-Steroidal Anti-Inflammatory Agents (NSAIDs) are used in clinical contexts related to mineral management. Regulatory labeling advises that all concurrent medicines, including those bought over the counter, should be known to a healthcare provider.


Q: Are there any specific foods or drinks that should be avoided when using Alcidol?

Official interaction warnings specifically document caution regarding a high intake of Dietary Phosphate, as this can lead to an imbalance with phosphorus. Also, official documents note that a diet markedly lacking in calcium may reduce the intended response of the medicine.


Q: Is there a generic version of Alcidol available?

Yes, the active ingredient in Alcidol is Alfacalcidol, and major regulatory agencies list multiple approved generic product names. These generics are typically available in various formulations, such as 'Alfacalcidol Capsules'.


Q: What is the difference between Alcidol and a placebo in clinical trials?

In regulatory-required clinical research, a placebo is a substance with no active drug, given to a comparison group. Alcidol, conversely, is the active drug being tested. Research studies are designed to scientifically evaluate the difference in health outcomes, such as changes in mineral metabolism, between the two groups.


Q: Is Alcidol addictive or habit-forming?

No. Alcidol is a Vitamin D analogue and a calcemic agent. It is not classified as an addictive or habit-forming substance by major national and international regulatory authorities.


Q: Why is it sometimes important to limit alcohol intake while using Alcidol?

Regulatory documents mention that some liquid formulations of Alcidol (such as oral drops) contain ethanol (alcohol) as an inactive ingredient, called an excipient. This alcohol content must be considered, especially for young children and individuals with alcoholism.


Q: How long does Alcidol stay in the body after the last dose?

Pharmacokinetic data from regulatory sources shows that the medicine’s half-life—the time it takes for the drug concentration to decrease by half—is approximately 3 to 4 hours. However, the drug’s long-acting active metabolite, calcitriol, remains in the body for longer, with a half-life of about 16 hours.


Q: Are there any long-term health risks associated with taking Alcidol?

The most significant long-term risk documented in official warnings relates to the potential consequence of prolonged high blood calcium (hypercalcaemia). This condition is documented to increase the risk of metastatic calcification (calcium deposits in soft tissues), kidney stone formation, and may aggravate existing cardiovascular diseases.


Q: Can Alcidol be safely used by children or adolescents?

Official documentation describes Alcidol as indicated for use in children (including neonates) for conditions involving disturbed calcium metabolism. The required dosage for children is determined based on body weight. Regulatory labels generally do not distinguish adolescents from the general pediatric age group.


Q: Are there any restrictions on driving or operating machinery while on Alcidol?

Official regulatory labels advise that Alcidol may sometimes cause side effects like fatigue or muscle weakness, which are linked to hypercalcaemia. If an individual experiences dizziness or weakness, regulatory labels indicate that their ability to drive or operate heavy machinery may be affected.


Q: Can Alcidol affect blood sugar levels?

Regulatory documents do not list an effect on blood sugar as a classified adverse reaction of the drug itself. However, official research contexts explore the use of Alcidol in patients who also have Type II diabetic nephropathy, indicating it is used in a population that requires careful blood sugar management.


Q: Is Alcidol used for acute or chronic conditions?

Alcidol is officially indicated for the management of chronic conditions that involve long-term disturbances in mineral metabolism, such as bone disorders related to chronic kidney disease. However, it may also be used to manage acute phases of certain low-calcium conditions, such as hypoparathyroidism.

How should Alcidol be stored and disposed of?

The required storage and disposal conditions for Alcidol (Alfacalcidol) are strictly defined by its pharmaceutical form, as the drug is sensitive to heat and light.

Formulation Storage Temperature Protection Requirement
Capsules Store at room temperature, not above 25 C or 30 C (varies by product). Protect from light and moisture.
Oral Drops / Injection Store refrigerated ( between 2 C and 8 C). Do not freeze. Keep in the outer carton.

All formulations must be kept out of the sight and reach of children, as required by regulatory agencies. For stability, opened oral drops must be discarded after 4 months even when refrigerated. Unused or expired Alcidol must not be disposed of in household waste or wastewater. Instead, patients are directed to return the product to a pharmacist or an approved special waste collection point for disposal in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alcidol found in:

A-Z Index: